Address liabilities pertaining to both cardiovascular — and non-cardiovascular — targeted drugs, earlier than ever before. “Frontloading” your program is a process where you address cardiovascular or seizure liability safety endpoints prior to the selection of your drug candidate. Although not mandated by the key regulatory guidance for safety pharmacology, an increasing number of companies choose to conduct early non-GLP safety studies in support of decisions on the progression of their compounds. These studies can be incorporated in Lead Optimization toxicology programs or integrated with mechanistic endpoints.
Start your discovery efficacy and early safety respiratory studies right with lead optimization in vivo and in vitro models.